Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Launched by NATIONAL CANCER INSTITUTE (NCI) · Sep 27, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining whether an immunotherapy drug called durvalumab can be added to standard chemotherapy treatments for patients with stage II-III hormone receptor positive, HER2 negative breast cancer. The goal is to see if combining durvalumab with chemotherapy drugs like paclitaxel, cyclophosphamide, and doxorubicin can help the immune system fight cancer more effectively and potentially prevent the cancer from coming back. This study is specifically looking at patients who have a certain genetic profile (MammaPrint Ultrahigh risk) that may respond better to this treatment.
To participate in this trial, patients need to be at least 18 years old and have confirmed hormone receptor positive, HER2 negative breast cancer. They should not have received any prior treatments for their breast cancer and must meet specific health criteria. Participants will receive either the usual chemotherapy alone or the chemotherapy plus durvalumab. Throughout the trial, patients can expect regular check-ups and assessments to monitor their health and response to the treatment. This trial is currently recruiting participants, and those interested should discuss it with their healthcare provider to see if they qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines
- • NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible
- • STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer
- • NOTE: Participants with inflammatory breast cancer are eligible
- • NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node
- • STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines
- • STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer
- • STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions
- • NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biopsies should be pursued
- • STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status
- * Submitting tissue for on-study MammaPrint testing:
- • Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment
- • NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network OR
- * Submitting prior known MammaPrint Index Score:
- • If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
- • NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to SWOG Cancer Research Network
- • NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study
- • NOTE: Participants enrolling with known MP2 status (i.e. MP already obtained as routine care) must only sign the treatment informed consent form. Screening consent is not required when MP2 status is known prior to study enrollment
- • STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy
- • STEP 1: REGISTRATION (SCREENING): Participants must be \>= 18 years old at the time of registration
- • STEP 1: REGISTRATION (SCREENING): Participants must have body weight \> 30 kg
- • STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2
- • STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- • STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
- • STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
- • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
- • STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration
- • STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result
- * For participants submitting tissue for on-study MammaPrint testing:
- • Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) from initial tumor biopsy OR
- * Submitting commercial MammaPrint Index Score:
- • If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy
- • NOTE: Participants without a MammaPrint High-Risk 2 score must not be registered to Step 2 Randomization
- • STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed
- • STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
- • STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2
- • STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within two years prior to Step 2: Randomization
- • STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2: Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
- • STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical exam within 28 days prior to Step 2: Randomization
- • STEP 2: RANDOMIZATION: Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
- • STEP 2: RANDOMIZATION: Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
- • STEP 2: RANDOMIZATION: Platelets \>= 100 x 10\^3/uL (within 28 days prior to Step 2: Randomization)
- • STEP 2: RANDOMIZATION: Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to Step 2: Randomization)
- • STEP 2: RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 × institutional ULN (within 28 days prior to Step 2: Randomization)
- • STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance \>= 50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to Step 2: Randomization
- • STEP 2: RANDOMIZATION: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
- • STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization
- • STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization
- • STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained while on suppressive therapy within 6 months prior to Step 2: Randomization, if indicated
- • STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization, if indicated
- • STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy
- • STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
- • STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study
- • STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- • STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
New Haven, Connecticut, United States
Milwaukee, Wisconsin, United States
Charleston, South Carolina, United States
Saint Louis, Missouri, United States
Flint, Michigan, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Edina, Minnesota, United States
Waconia, Minnesota, United States
Maywood, Illinois, United States
Loma Linda, California, United States
Detroit, Michigan, United States
Newark, New Jersey, United States
Toms River, New Jersey, United States
Staten Island, New York, United States
Oklahoma City, Oklahoma, United States
Duarte, California, United States
Des Moines, Iowa, United States
Green Bay, Wisconsin, United States
Knoxville, Tennessee, United States
Long Branch, New Jersey, United States
Cleveland, Ohio, United States
Baltimore, Maryland, United States
Saint Paul, Minnesota, United States
Ann Arbor, Michigan, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Bozeman, Montana, United States
Delaware, Ohio, United States
Houston, Texas, United States
Mount Vernon, Illinois, United States
Salina, Kansas, United States
Gresham, Oregon, United States
Tualatin, Oregon, United States
Bryn Mawr, Pennsylvania, United States
Coon Rapids, Minnesota, United States
Urbana, Illinois, United States
Carroll, Iowa, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Shakopee, Minnesota, United States
Dayton, Ohio, United States
Effingham, Illinois, United States
Lawrence, Kansas, United States
Bethlehem, Pennsylvania, United States
Clearwater, Florida, United States
Springfield, Illinois, United States
Houston, Texas, United States
Downers Grove, Illinois, United States
Portland, Oregon, United States
Roseville, California, United States
Hazel Crest, Illinois, United States
Springfield, Illinois, United States
Media, Pennsylvania, United States
Summit, New Jersey, United States
Washington, District Of Columbia, United States
Pittsburgh, Pennsylvania, United States
San Antonio, Texas, United States
Minneapolis, Minnesota, United States
Danville, Pennsylvania, United States
Birmingham, Alabama, United States
Tucson, Arizona, United States
Modesto, California, United States
Orange, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
Duluth, Minnesota, United States
Saint Louis, Missouri, United States
New Brunswick, New Jersey, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Syracuse, New York, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Charleston, South Carolina, United States
Lexington, Kentucky, United States
Columbus, Ohio, United States
Tulsa, Oklahoma, United States
Allentown, Pennsylvania, United States
Morgantown, West Virginia, United States
Providence, Rhode Island, United States
Cape Girardeau, Missouri, United States
Robbinsdale, Minnesota, United States
Saint Louis Park, Minnesota, United States
Memphis, Tennessee, United States
Beverly Hills, California, United States
Glens Falls, New York, United States
Bethlehem, Pennsylvania, United States
Milwaukee, Wisconsin, United States
Oak Lawn, Illinois, United States
Tampa, Florida, United States
Park Ridge, Illinois, United States
Stony Brook, New York, United States
Houston, Texas, United States
Richmond, Virginia, United States
Sacramento, California, United States
Detroit, Michigan, United States
Morristown, New Jersey, United States
Mineola, New York, United States
Green Bay, Wisconsin, United States
Marshfield, Wisconsin, United States
Portland, Oregon, United States
Miami Beach, Florida, United States
Decatur, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Beverly, Massachusetts, United States
Gloucester, Massachusetts, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Jackson, Michigan, United States
Lansing, Michigan, United States
Warren, Michigan, United States
Brainerd, Minnesota, United States
Palm Springs, California, United States
New York, New York, United States
Los Angeles, California, United States
Pontiac, Michigan, United States
Maplewood, Minnesota, United States
Great Falls, Montana, United States
Wilkes Barre, Pennsylvania, United States
Baltimore, Maryland, United States
Scranton, Pennsylvania, United States
Paoli, Pennsylvania, United States
San Francisco, California, United States
Hartford, Connecticut, United States
Jupiter, Florida, United States
Atlanta, Georgia, United States
Galesburg, Illinois, United States
Kansas City, Kansas, United States
Topeka, Kansas, United States
Battle Creek, Michigan, United States
Saginaw, Michigan, United States
Springfield, Missouri, United States
Billings, Montana, United States
Missoula, Montana, United States
Reno, Nevada, United States
Newark, New Jersey, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Sylvania, Ohio, United States
Troy, Ohio, United States
Portland, Oregon, United States
East Stroudsburg, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Richmond, Virginia, United States
South Hill, Virginia, United States
Tacoma, Washington, United States
Green Bay, Wisconsin, United States
Minocqua, Wisconsin, United States
Oconto Falls, Wisconsin, United States
Rice Lake, Wisconsin, United States
Sheboygan, Wisconsin, United States
West Allis, Wisconsin, United States
Weston, Wisconsin, United States
Berkeley, California, United States
Palo Alto, California, United States
San Francisco, California, United States
Savannah, Georgia, United States
Burlington, Massachusetts, United States
Hamilton, New Jersey, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Libertyville, Illinois, United States
Livonia, Michigan, United States
Mansfield, Ohio, United States
Newberg, Oregon, United States
Oshkosh, Wisconsin, United States
Munster, Indiana, United States
Boise, Idaho, United States
Charleston, West Virginia, United States
Moline, Illinois, United States
Duluth, Minnesota, United States
White Plains, New York, United States
Tucson, Arizona, United States
Elgin, Illinois, United States
Pasadena, California, United States
Torrington, Connecticut, United States
Goldsboro, North Carolina, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Boise, Idaho, United States
Somerville, New Jersey, United States
Fargo, North Dakota, United States
Appleton, Wisconsin, United States
Warrenville, Illinois, United States
Shreveport, Louisiana, United States
Grafton, Wisconsin, United States
Greenville, South Carolina, United States
Greenville, South Carolina, United States
Portland, Oregon, United States
Atlanta, Georgia, United States
Mount Kisco, New York, United States
Fort Smith, Arkansas, United States
Santa Rosa, California, United States
Vallejo, California, United States
Edwards, Colorado, United States
Post Falls, Idaho, United States
Bloomington, Illinois, United States
Chicago, Illinois, United States
Geneva, Illinois, United States
Pekin, Illinois, United States
Monroe, Louisiana, United States
Lansing, Michigan, United States
Saint Louis, Missouri, United States
New York, New York, United States
Bend, Oregon, United States
Erie, Pennsylvania, United States
Harrisburg, Pennsylvania, United States
Boiling Springs, South Carolina, United States
Easley, South Carolina, United States
Georgetown, South Carolina, United States
Greenville, South Carolina, United States
Greenville, South Carolina, United States
Greer, South Carolina, United States
Seneca, South Carolina, United States
Burlington, Wisconsin, United States
Germantown, Wisconsin, United States
Green Bay, Wisconsin, United States
Kenosha, Wisconsin, United States
Marinette, Wisconsin, United States
Milwaukee, Wisconsin, United States
Racine, Wisconsin, United States
Summit, Wisconsin, United States
Two Rivers, Wisconsin, United States
Wauwatosa, Wisconsin, United States
South Pasadena, California, United States
Santa Rosa, California, United States
Olathe, Kansas, United States
Saint Louis, Missouri, United States
Oklahoma City, Oklahoma, United States
Erie, Pennsylvania, United States
Richmond, Virginia, United States
Jonesboro, Arkansas, United States
Sunnyvale, California, United States
Atlanta, Georgia, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Overland Park, Kansas, United States
Bel Air, Maryland, United States
Kansas City, Missouri, United States
Lee's Summit, Missouri, United States
Oregon City, Oregon, United States
Monroeville, Pennsylvania, United States
Fredericksburg, Virginia, United States
Edmonds, Washington, United States
Issaquah, Washington, United States
Lacey, Washington, United States
Vancouver, Washington, United States
Springfield, Illinois, United States
Columbus, Ohio, United States
Delaware, Ohio, United States
Lancaster, California, United States
Saint Peters, Missouri, United States
Beaver, Pennsylvania, United States
Greensburg, Pennsylvania, United States
Johnstown, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Knoxville, Tennessee, United States
New York, New York, United States
Great Falls, Montana, United States
Auburn, California, United States
Santa Cruz, California, United States
Newark, Delaware, United States
Newark, Delaware, United States
Rehoboth Beach, Delaware, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Sandpoint, Idaho, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Caro, Michigan, United States
Chelsea, Michigan, United States
East China Township, Michigan, United States
Farmington Hills, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Macomb, Michigan, United States
Saginaw, Michigan, United States
Warren, Michigan, United States
West Branch, Michigan, United States
Ypsilanti, Michigan, United States
Anaconda, Montana, United States
Las Vegas, Nevada, United States
Clinton, North Carolina, United States
Jacksonville, North Carolina, United States
Centerville, Ohio, United States
Dublin, Ohio, United States
Marion, Ohio, United States
Ontario, Oregon, United States
Lewisburg, Pennsylvania, United States
Anchorage, Alaska, United States
Lexington, Kentucky, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
O'fallon, Illinois, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Clinton Township, Michigan, United States
Novi, Michigan, United States
West Bloomfield, Michigan, United States
Ypsilanti, Michigan, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sturgeon Bay, Wisconsin, United States
Richmond, Virginia, United States
Bakersfield, California, United States
Westminster, Maryland, United States
Norton Shores, Michigan, United States
Novi, Michigan, United States
Columbus, Mississippi, United States
Grenada, Mississippi, United States
New Albany, Mississippi, United States
Oxford, Mississippi, United States
Southhaven, Mississippi, United States
Creve Coeur, Missouri, United States
Saint Louis, Missouri, United States
Henderson, Nevada, United States
Eau Claire, Wisconsin, United States
Fremont, California, United States
Wexford, Pennsylvania, United States
Milwaukee, Wisconsin, United States
Elizabeth, New Jersey, United States
Charleston, South Carolina, United States
Charleston, South Carolina, United States
Menomonee Falls, Wisconsin, United States
West Bend, Wisconsin, United States
Trumbull, Connecticut, United States
Des Moines, Iowa, United States
Overland Park, Kansas, United States
Westwood, Kansas, United States
Winter Haven, Florida, United States
Midlothian, Virginia, United States
Glen Burnie, Maryland, United States
North Kansas City, Missouri, United States
Jefferson Hills, Pennsylvania, United States
Tawas City, Michigan, United States
Las Vegas, Nevada, United States
Lakewood, New Jersey, United States
Seattle, Washington, United States
New York, New York, United States
Derby, Connecticut, United States
Fairfield, Connecticut, United States
North Haven, Connecticut, United States
Waterbury, Connecticut, United States
Waterford, Connecticut, United States
Dekalb, Illinois, United States
Charleston, South Carolina, United States
Stevens Point, Wisconsin, United States
Johns Creek, Georgia, United States
Greenwich, Connecticut, United States
Deer River, Minnesota, United States
Hibbing, Minnesota, United States
Sandstone, Minnesota, United States
Virginia, Minnesota, United States
Hazleton, Pennsylvania, United States
Bluffton, South Carolina, United States
Hilton Head Island, South Carolina, United States
Collierville, Tennessee, United States
Ashland, Wisconsin, United States
Jersey City, New Jersey, United States
Fort Dodge, Iowa, United States
Easton, Pennsylvania, United States
Mechanicsville, Virginia, United States
Lake Forest, Illinois, United States
Cary, North Carolina, United States
Garner, North Carolina, United States
Oak Ridge, Tennessee, United States
Brighton, Michigan, United States
Mechanicsburg, Pennsylvania, United States
Oak Creek, Wisconsin, United States
Libertyville, Illinois, United States
Dixon, Illinois, United States
Washington, Illinois, United States
Farmington, Missouri, United States
San Mateo, California, United States
Santa Rosa, California, United States
Tarzana, California, United States
Upland, California, United States
Frankford, Delaware, United States
Peabody, Massachusetts, United States
Burnsville, Minnesota, United States
York, Pennsylvania, United States
San Juan, , Puerto Rico
Bozeman, Montana, United States
Irvine, California, United States
Stamford, Connecticut, United States
Barrington, Illinois, United States
Crystal Lake, Illinois, United States
Crown Point, Indiana, United States
Dyer, Indiana, United States
Hobart, Indiana, United States
Hobart, Indiana, United States
Indianapolis, Indiana, United States
Munster, Indiana, United States
Valparaiso, Indiana, United States
Oswego, New York, United States
Sleepy Hollow, New York, United States
Dublin, Ohio, United States
Butler, Pennsylvania, United States
Cranberry Township, Pennsylvania, United States
Indiana, Pennsylvania, United States
Monroeville, Pennsylvania, United States
Washington, Pennsylvania, United States
West Mifflin, Pennsylvania, United States
Williamsport, Pennsylvania, United States
Cudahy, Wisconsin, United States
Glastonbury, Connecticut, United States
Neenah, Wisconsin, United States
New York, New York, United States
Westerly, Rhode Island, United States
Vancouver, Washington, United States
Highlands Ranch, Colorado, United States
Raleigh, North Carolina, United States
Missoula, Montana, United States
Torrance, California, United States
Lone Tree, Colorado, United States
Brooklyn, New York, United States
Torrance, California, United States
Newport Beach, California, United States
Nampa, Idaho, United States
Springfield, Illinois, United States
Denver, Colorado, United States
Long Beach, California, United States
Aurora, Colorado, United States
Shiloh, Illinois, United States
Sheboygan, Wisconsin, United States
Safety Harbor, Florida, United States
Mineola, New York, United States
Raleigh, North Carolina, United States
Kansas City, Missouri, United States
Cumberland, Maryland, United States
Des Moines, Iowa, United States
Allentown, Pennsylvania, United States
Lebanon, New Hampshire, United States
Moon, Pennsylvania, United States
Wyoming, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Nampa, Idaho, United States
Pontiac, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Dayton, Ohio, United States
San Juan, , Puerto Rico
Danville, Illinois, United States
Guilford, Connecticut, United States
Orland Park, Illinois, United States
Quakertown, Pennsylvania, United States
Greenville, Ohio, United States
Decatur, Georgia, United States
Canton, Michigan, United States
Minocqua, Wisconsin, United States
Columbia, Missouri, United States
Stroudsburg, Pennsylvania, United States
Verona, New York, United States
Glenview, Illinois, United States
Grayslake, Illinois, United States
Ankeny, Iowa, United States
Sunset Hills, Missouri, United States
Niles, Michigan, United States
Reed City, Michigan, United States
Saint Joseph, Michigan, United States
Aberdeen, Maryland, United States
Des Moines, Iowa, United States
Clive, Iowa, United States
Lansing, Michigan, United States
Shreveport, Louisiana, United States
Grand Rapids, Michigan, United States
Rockford, Illinois, United States
Hays, Kansas, United States
Escanaba, Michigan, United States
Saint Joseph, Michigan, United States
Jefferson City, Missouri, United States
Dayton, Ohio, United States
Royal Oak, Michigan, United States
Sandpoint, Idaho, United States
Ontario, Oregon, United States
Irvine, California, United States
Dearborn, Michigan, United States
Farmington Hills, Michigan, United States
Troy, Michigan, United States
Millville, Delaware, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Pickerington, Ohio, United States
Westerville, Ohio, United States
Southfield, Michigan, United States
Novi, Michigan, United States
Detroit, Michigan, United States
Flint, Michigan, United States
Warren, Michigan, United States
East China Township, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Olathe, Kansas, United States
Grosse Pointe Woods, Michigan, United States
Mount Vernon, Illinois, United States
Ankeny, Iowa, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Hood River, Oregon, United States
Southampton, New York, United States
Patients applied
Trial Officials
Erin F Cobain
Principal Investigator
SWOG Cancer Research Network
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported